NCT02475642Unknown4 期
Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF)
VZW Cardiovascular Research Center Aalst4 个研究点 分布在 1 个国家目标入组 152 人开始时间: 2014年3月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 152
- 试验地点
- 4
- 主要终点
- Efficacy as measured by freedom of arrhythmia recurrence
研究概览
简要总结
The purpose of this study is to compare the efficacy and safety of PV isolation with continued antiarrhythmic drug treatment (PVI+ADT) to PV isolation without continued ADT (PVI-ADT) in patients undergoing treatment for symptomatic recurrent AF.
详细描述
Subjects that underwent PV isolation for paroxysmal or non-longstanding persistent AF and are free of arrhythmia at the end of the 3-month blanking period while taking ADT. Eligible subjects who sign the study informed consent form will be randomized into one of two study arms:
PVI+ADT Group: continue ADT through 9 months follow-up PVI-ADT Group: no ADT through 9 months follow up
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patient has continued (IC or III) ADT throughout the 3-month blanking
- •patient is free of symptomatic and asymptomatic AF (as evidenced by 1-day Holter) at the 3-month visit
- •drug-resistant (at least one class IC or III) symptomatic AF was the primary indication for prior PV isolation
- •in the three months prior to PVI, at least one episode of symptomatic or asymptomatic AF
- •PV isolation was performed according to the standards set forward by the Task Force Document (sedation or general anesthesia)
- •PV isolation was the only target for ablation (except for cavotricuspid (CTI) ablation if documented AFL)
- •PV isolation was performed by point-by-point irrigated radio frequency (RF) guided by contact-force (Biosense) (10-30gr-continuous lesion)
- •PV isolation (i.e. entry block) was verified in each vein after a waiting time and adenosine (with continued RF if acute reconnection)
- •Signed Patient Informed Consent Form.
- •Age 18 years or older.
- •Able and willing to comply with all follow-up testing and requirements.
排除标准
- •Longstanding persistent atrial fibrillation (>12 months of continuous AF)
- •Previous ablation for AF
- •left atrium (LA) size > 55 mm
- •left ventricular ejection fraction (LVEF) < 40%
- •AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause
- •coronary artery bypass graft (CABG) procedure within the last six months
- •Awaiting cardiac transplantation or other cardiac surgery
- •Documented left atrial thrombus on imaging
- •Diagnosed atrial myxoma
- •Women who are pregnant (by history of menstrual period or pregnancy test if the history is considered unreliable) or breastfeeding
- •Acute illness or active systemic infection or sepsis
- •Unstable angina
- •Uncontrolled heart failure
- •Myocardial infarction within the previous two (2) months
- •History of blood clotting or bleeding abnormalities
- •Contraindication to anticoagulation therapy (ie, heparin or warfarin)
- •Life expectancy less than 12 months
- •Enrollment in any other study evaluating another device or drug
- •Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction
- •Patients not taking any class IC or III ADT at 3 months after PV isolation
- •No documentation of entry block at initial PV isolation - no waiting time or adenosine.
- •Additional linear ablation or defractionation during the initial procedure (except for CTI ablation for documented or induced cavo-tricuspid isthmus dependent flutter).
结局指标
主要结局
Efficacy as measured by freedom of arrhythmia recurrence
时间窗: 9 months
Arrhythmia recurrence rate at 1 year post ablation (9 months post randomization)
Safety as measured by drug discontinuation
时间窗: 9 months
Number of participants with any adverse events at 1 year post ablation (9 months post randomization) leading to drug discontinuation
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
进行中（未招募）
1 期
Continuing versus stopping heart rhythm medication after an operation restoring your normal heart rhythm in patients with a heart rhythm disorder: a study across multiple hospitals.Symptomatic persistent atrial fibrillation: atrial fibrillation, that lasts longer than 7 days, including episodes that are terminated by cardioversion, either with drugs or by direct current cardioversion, after 7 days or more. Episodes of atrial fibrillation have to be accompanied by symptoms.MedDRA version: 20.0Level: LLTClassification code 10071667Term: Persistent atrial fibrillationSystem Organ Class: 100000004849EUCTR2018-002103-33-DKAZ Sint-Jan Brugge-Oostende AV220
进行中（未招募）
1 期
Continuing versus stopping heart rhythm medication after an operation restoring your normal heart rhythm in patients with a heart rhythm disorder: a study across multiple hospitals.Symptomatic persistent atrial fibrillation: atrial fibrillation, that lasts longer than 7 days, including episodes that are terminated by cardioversion, either with drugs or by direct current cardioversion, after 7 days or more. Episodes of atrial fibrillation have to be accompanied by symptoms.MedDRA version: 20.0 Level: LLT Classification code 10071667 Term: Persistent atrial fibrillation System Organ Class: 100000004849EUCTR2018-002103-33-ESAZ Sint-Jan Brugge-Oostende AV220
进行中（未招募）
1 期
Continuing versus stopping heart rhythm medication after an operation restoring your normal heart rhythm in patients with a heart rhythm disorder: a study across multiple hospitals.Symptomatic persistent atrial fibrillation: atrial fibrillation, that lasts longer than 7 days, including episodes that are terminated by cardioversion, either with drugs or by direct current cardioversion, after 7 days or more. Episodes of atrial fibrillation have to be accompanied by symptoms.MedDRA version: 20.0 Level: LLT Classification code 10071667 Term: Persistent atrial fibrillation System Organ Class: 100000004849EUCTR2018-002103-33-FRAZ Sint-Jan Brugge-Oostende AV220
进行中（未招募）
1 期
Continuing versus stopping heart rhythm medication after an operation restoring your normal heart rhythm in patients with a heart rhythm disorder: a study across multiple hospitals.Symptomatic persistent atrial fibrillation: atrial fibrillation, that lasts longer than 7 days, including episodes that are terminated by cardioversion, either with drugs or by direct current cardioversion, after 7 days or more. Episodes of atrial fibrillation have to be accompanied by symptoms.MedDRA version: 20.0 Level: LLT Classification code 10071667 Term: Persistent atrial fibrillation System Organ Class: 100000004849EUCTR2018-002103-33-ATAZ Sint-Jan Brugge-Oostende AV220
已完成
不适用
The Comparison Between the PVAM and CPVI for the Patients of PAFPulmonary Vein IsolationAtrial FibrillationNCT03026413The First Affiliated Hospital with Nanjing Medical University180